Abnormal Flagging of Prostate Specific Antigen Screening Tests: A Regression Discontinuity Design
While the use of PSA ULN has recognized shortcomings, abnormal flagging of results above this threshold strongly influences additional testing, referral, and biopsy, potentially leading to risk-discordant over- and under-evaluation. An improved reporting standard may include risk estimates of meaningful endpoints such as the risk of prostate cancer metastasis or death.
Authors
- Todd Matthew Morgan (ORCID: https://orcid.org/0000-0002-1140-0603)
- Patrick Lewicki (ORCID: https://orcid.org/0000-0002-0692-2909)
- Ralph Jiang (ORCID: https://orcid.org/0000-0001-9940-4109)
- Matthew J. Schipper (ORCID: https://orcid.org/0000-0001-6728-4720)
- Archana Radhakrishnan (ORCID: https://orcid.org/0000-0001-7689-6390)
- Kristian Stensland (ORCID: https://orcid.org/0000-0002-4917-2984)
Institutions
- University of Michigan (US)
- Michigan Medicine (US)
Publication Details
- Journal
- Journal of General Internal Medicine
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1007/s11606-025-10075-x
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases